Related Experiment Video

Updated: May 25, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Genetic insight and therapeutic targets in squamous-cell lung cancer

M L Sos1, R K Thomas

  • 1Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany.

Oncogene
|January 24, 2012
PubMed

Insights

Squamous-cell lung cancer lacks targeted therapies. Recent genomic studies reveal fibroblast growth factor receptor 1 amplifications and discoidin domain receptor 2 mutations as potential new treatment targets.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Squamous-cell lung cancer (SCC) is a major global cancer subtype, strongly associated with tobacco use.
  • Current targeted therapies, like epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors, are ineffective for SCC, unlike in lung adenocarcinomas.
  • There is a critical need for novel therapeutic strategies for squamous-cell lung cancer.

Purpose of the Study:

  • To review recent genomic discoveries in squamous-cell lung cancer.
  • To highlight potential novel therapeutic targets, including fibroblast growth factor receptor 1 (FGFR1) and discoidin domain receptor 2 (DDR2).
  • To discuss the implications of these findings for future clinical trials in SCC.

Main Methods:

  • Review of recent scientific literature and genomic characterization studies of squamous-cell lung cancer.
  • Analysis of identified genetic alterations, specifically FGFR1 amplifications and DDR2 mutations.
  • Evaluation of the potential of targeting these alterations in therapeutic strategies.

Main Results:

  • Genomic characterization has identified specific alterations in squamous-cell lung cancer.
  • Fibroblast growth factor receptor 1 gene amplifications represent a potential therapeutic target.
  • Discoidin domain receptor 2 gene mutations are also identified as a potential target for SCC treatment.

Conclusions:

  • Novel therapeutic targets, FGFR1 and DDR2, have emerged from recent squamous-cell lung cancer genomic research.
  • These discoveries offer new avenues for developing targeted treatments for patients with squamous-cell lung cancer.
  • Further clinical trials are warranted to assess the efficacy of therapeutics targeting FGFR1 and DDR2 in SCC.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...